A CONSENSUS ON RISK MITIGATION FOR BROLUCIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Patient Selection, Evaluation, and Treatment

PURPOSE: Brolucizumab has high efficacy in retinal fluid resolution and provides the possibility for longer dosing intervals in the treatment of neovascular age-related macular degeneration. However, brolucizumab has been associated with events of retinal vasculitis and retinal vascular occlusion ty...

Descripción completa

Detalles Bibliográficos
Autores principales: Holz, Frank G., Iida, Tomohiro, Maruko, Ichiro, Sadda, SriniVas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387760/
https://www.ncbi.nlm.nih.gov/pubmed/35994582
http://dx.doi.org/10.1097/IAE.0000000000003556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387760/
https://www.ncbi.nlm.nih.gov/pubmed/35994582
http://dx.doi.org/10.1097/IAE.0000000000003556

Ejemplares similares